rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VANI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Vivani Medical Announces Private Placement Equity Financing
      Nov 16Yahoo FinanceVANI
      Vivani Medical CBO Donald Dwyer buys $19,645 of company stock
      Nov 14Investing.comVANI
      Why Is Vivani Medical Stock Soaring Today? - Vivani Medical (NASDAQ:VANI)
      Nov 12BenzingaVANI
      Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects
      Nov 12Yahoo FinanceVANI
      Vivani Medical: Q3 Earnings Snapshot
      Nov 11Yahoo FinanceVANI
      Vivani Medical merger with ClearOne awaits final regulatory approval
      Oct 30Investing.comCLROVANI
      Vivani Medical announces anticipated October closing of Cortigent merger with ClearOne
      Sep 16Investing.comCLROVANI
      Vivani Medical at H.C. Wainwright conference: implant pitch gains pace
      Sep 11Investing.comVANI
      Vivani Medical Announces Participation in Upcoming Investor Conferences

      ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its planned participation in two upcoming investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth ConferenceSeptember 10, 2026Metropolitan ClubNew York, New YorkH.C. Wainwright 28th Annual Global

      Sep 3Yahoo FinanceVANI
      Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? | The Motley Fool

      Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

      Aug 29The Motley FoolVANILLY

      This is the newest page. Registered accounts read further back.